Related Experiment Video
Updated: Sep 14, 2025
Using RNA-sequencing to Detect Novel Splice Variants Related to Drug Resistance in In Vitro Cancer Models
Published on: December 9, 2016
Pitavastatin overcomes multi-drug resistance in CRC and NSCLC by targeting the NRP1-ZFX axis
Yuan-Yuan Zhai1, Qiang Wang1, Qi-Yao Nong1
1Key Laboratory of Drug Quality Control and Pharmacovigilance (Ministry of Education), State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China.
Abstract:
Multidrug resistance (MDR) is a significant challenge in cancer treatment, with limited effective strategies available. Neuropilin-1 (NRP1) is emerging as a potential therapeutic target for overcoming drug resistance, but its role in MDR and the identification of potential inhibitors require further exploration. In this study, we investigated the role of NRP1 in MDR and identifies potential inhibitors targeting NRP1. Elevated NRP1 expression was observed in oxaliplatin (OXP)-resistant HCT116 (HCT116/L) and cisplatin (DDP)-resistant A549 cells (A549/DDP). Virtual screening and biological assays identified pitavastatin (Ptv) as a potent NRP1 inhibitor that restored chemosensitivity in resistant cells both in vitro and in vivo. Mechanistic studies revealed that Ptv directly binds to NRP1, promotes degradation of Zinc finger X-chromosomal protein (ZFX), and disrupts the NRP1-ZFX axis to reverse MDR. This study provides promising prospects for targeting the NRP1-ZFX axis as a therapeutic strategy for MDR and highlights the potential clinical application of Ptv in diseases involving NRP1.
Insights
Pitavastatin inhibits Neuropilin-1 (NRP1) and reverses multidrug resistance (MDR) in cancer cells by disrupting the NRP1-ZFX pathway. This finding offers a new therapeutic strategy for overcoming drug resistance in cancer treatment.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Multidrug resistance (MDR) poses a major obstacle in cancer therapy.
- Neuropilin-1 (NRP1) is a potential target for overcoming MDR, but its role and inhibitors need further study.
Purpose of the Study:
- To investigate NRP1's role in MDR.
- To identify potential NRP1 inhibitors for reversing MDR.
Main Methods:
- Virtual screening and biological assays were used to identify inhibitors.
- In vitro and in vivo experiments assessed pitavastatin's efficacy.
- Mechanistic studies explored the NRP1-ZFX axis.
Main Results:
- Elevated NRP1 expression was found in drug-resistant cancer cells.
- Pitavastatin (Ptv) was identified as a potent NRP1 inhibitor.
- Ptv restored chemosensitivity by degrading ZFX and disrupting the NRP1-ZFX axis.
Conclusions:
- Targeting the NRP1-ZFX axis is a promising strategy for MDR.
- Pitavastatin shows potential for clinical application in NRP1-related diseases.
More Related Videos
09:29Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
Published on: September 30, 2016
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...